XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
F
F

Fresenius

News

Reuters - 1 week ago

ASML Holding, Aviva, HSBC

EUROPE RESEARCH ROUNDUP-ASML Holding, Aviva, HSBC Nov 15 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including ASML Holding, Aviva, and HSBC on Friday. HIGHLIGHTS * ASML Holding NV ASML.AS : Jefferies raises target price to EUR 840 from EUR 760 * Aviva AV.L : HSBC raises to buy from hold * CVC Capital Partners Plc CVC.AS : Citigroup cuts to neutral from buy * HSBC HSBA.L : JP Morgan raises target price to 730p from 700p * Spirax Group SP
3
A
A
A
B
B
D
D
E
E
E
E
E
F
H
H
K
N
A
A
G
J
Reuters - 2 weeks ago

Anima Holding, BASF, Cargotec

EUROPE RESEARCH ROUNDUP-Anima Holding, BASF, Cargotec Nov 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Anima Holding, BASF and Cargotec on Monday. HIGHLIGHTS * Anima Holding ANIM.MI : HSBC cuts to hold from buy * BASF SE BASFn.DE : Goldman Sachs raises to buy * Cargotec Corp CGCBV.HE : Kepler Cheuvreux raises to hold from reduce * Compagnie Financiere Richemont SA CFR.S : HSBC raises to buy from hold * DS Smith SMDS.L : Barcl
A
A
A
A
B
B
B
C
D
E
F
F
H
H
I
R
R
S
A
A
B
B
B
C
D
M
Reuters - 2 weeks ago

Compass Group, Pandora, SSP Group

EUROPE RESEARCH ROUNDUP-Compass Group, Pandora, SSP Group Nov 7 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Compass Group, Pandora and SSP Group, on Thursday. HIGHLIGHTS * Compass Group CPG.L : Jefferies raises target price to 3,000p from 2,500p * Just Eat Takeaway.Com JETJ.L : JP Morgan raises target price to 1,415p from 1,396p * Marks and Spencer Group MKS.L : JP Morgan raises target price to 440p from 425p * Pandora PNDORA.C
A
B
C
C
E
F
F
G
G
I
K
M
P
P
S
S
S
S
S
Z
A
Reuters - 2 weeks ago

Fresenius soars on Q3 beat across the board

BUZZ-Fresenius soars on Q3 beat across the board ** German healthcare company Fresenius FREG.DE rises 6.6% after the company reported better-than-expected third-quarter results . ** The company reported a 7% increase in group revenues to 5.3 billion euros and a 8% increase in adjusted EBIT, which came in at 552 million euros. ** The results were "ahead of consensus expectations across the board", Berenberg said ** "The better-than-expected performance was driven by core operating performance and
F
F
G
Reuters - 2 weeks ago

Fresenius SE Q3 Revenue At EUR 5.30 Bln Versus EUR 5.21 Bln Consensus

BRIEF-Fresenius SE Q3 Revenue At EUR 5.30 Bln Versus EUR 5.21 Bln Consensus Nov 6 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : Q3 REVENUE AT EUR 5.30 BILLION VERSUS EUR 5.21 BILLION CONSENSUS UPGRADES 2024 OUTLOOK FOR EBIT BEFORE SPECIAL ITEMS GROWTH TO 8%-11% FROM 6%-10% Q3 EBIT BEFORE SPECIAL ITEMS AT EUR 552 MILLION VERSUS EUR 533.8 MILLION CONS
F
Reuters - 2 weeks ago

Germany's Fresenius raises 2024 forecast after Q3 beat

UPDATE 2-Germany's Fresenius raises 2024 forecast after Q3 beat, shares rise Adds share move in paragraph 4, analyst comment in paragraph 6, FMC result in paragraph 7, net debt in paragraph 8, savings objective in paragraph 11 By Tristan Veyet and Rafal Wojciech Nowak Nov 6 (Reuters) - Germany's Fresenius FREG.DE raised its full-year outlook on Wednesday after beating third-quarter expectations, citing strong performances at its Kabi and Helios divisions and deleveraging efforts paying off , sen
F
F
Reuters - 2 weeks ago

Germany's Fresenius raises 2024 forecast

Germany's Fresenius raises 2024 forecast Nov 6 (Reuters) - Germany's Fresenius FREG.DE raised its full-year outlook on Wednesday after beating third-quarter expectations, citing strong performances at its Kabi and Helios divisions. The healthcare group said it expects organic revenue growth of 6%-8%, from a previously anticipated 4%-7%. It also raised its forecast of constant currency earnings before interests and taxes (EBIT) before special items growth to 8%-11% from 6-10%.
F
Reuters - 3 weeks ago

Germany corporate earnings week ahead

DIARY-Germany corporate earnings week ahead Nov 1 (Reuters) - Diary of Germany (.GDAXI) corporate earnings for the week ahead GERMANY EARNINGS Start Date Start Time(GMT) RIC Company Name Event Name 05-Nov-2024 06:00 ZALG.DE Zalando SE Q3 2024 Zalando SE Earnings Release 05-Nov-2024 06:00 DHLn.DE Deutsche Post AG Q3 2024 Deutsche Post AG Earnings Release 06-Nov-2024 NTS VNAn.DE Vonovia SE Q3 2024 Vonovia SE Earnings Release 06-Nov-2024 BMO CBKG.DE Commerzbank AG Q3 2024 Commerzbank AG Earnings Re
B
C
F
H
R
S
V
Z
G
Reuters - 4 weeks ago

Glencore, Knaus Tabbert, LSE

EUROPE RESEARCH ROUNDUP- Glencore, Knaus Tabbert, LSE Oct 28 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Glencore, Knaus Tabbert and LSE, on Monday. HIGHLIGHTS * Glencore Plc GLEN.L : HSBC raises to buy from hold * Knaus Tabbert AG KTAG.DE : Jefferies cuts to hold from buy * LSE LSEG.L : RBC raises target price to 11,600p from 11,000p * Suzano SUZB3.SA : HSBC raises to buy from hold * Veolia VIE.PA : RBC initiates coverage with
A
B
D
E
E
E
E
F
G
H
H
H
I
K
R
R
R
S
S
U
V
B
E
S
Y
Reuters - 1 month ago

Fresenius And Cellular Origins Announce Development Agreement For Cell And Gene Therapy Manufacturing

BRIEF-Fresenius And Cellular Origins Announce Development Agreement For Cell And Gene Therapy Manufacturing Oct 16 (Reuters) - Fresenius SE & Co KGaA FREG.DE : FRESENIUS AND CELLULAR ORIGINS ANNOUNCE DEVELOPMENT AGREEMENT FOR CELL AND GENE THERAPY MANUFACTURING Further company coverage: FREG.DE (Gdansk Newsroom) ;))
F
Reuters - 2 months ago

Fresenius looking to boost output after hurricane damage at rival Baxter

UPDATE 4-Fresenius looking to boost output after hurricane damage at rival Baxter Updates Oct 8 story to add additional Fresenius comment, paragraph 4 FRANKFURT, Oct 9 (Reuters) - Germany's Fresenius FREG.DE said it was checking options to speed up the start of new production lines of medical equipment at a North Carolina facility to help mitigate potential shortages from hurricane damage to rival Baxter's BAX.N site in the same state.
F
F
Reuters - 2 months ago

Fresenius looking to boost production after hurricane damage at Baxter

Fresenius looking to boost production after hurricane damage at Baxter FRANKFURT, Oct 8 (Reuters) - Germany's Fresenius FREG.DE said it is checking options to start new infusion-solution production lines faster than planned at a North Carolina facility to help mitigate potential shortages due to the impact of Hurricane Helene on rival Baxter's North Cove site in the same state.
F
Reuters - 2 months ago

Fresenius: mAbxience And Teva Announce Second Strategic Global License Agreement For Biosimilar Oncology Treatment Candidate

BRIEF-Fresenius: mAbxience And Teva Announce Second Strategic Global License Agreement For Biosimilar Oncology Treatment Candidate Oct 3 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : MABXIENCE AND TEVA ANNOUNCE SECOND STRATEGIC GLOBAL LICENSE AGREEMENT FOR BIOSIMILAR ONCOLOGY TREATMENT CANDIDATE FRESENIUS SE - AGREEMENT COVERS GLOBAL MARKETS, INCLUD
F
Reuters - 2 months ago

FDA Says Identified Fresenius Kabi USA's Recall For Correction Of Ivenix Infusion System Lvp Software As Most Serious Type

BRIEF-FDA Says Identified Fresenius Kabi USA's Recall For Correction Of Ivenix Infusion System Lvp Software As Most Serious Type Oct 1 (Reuters) - FDA: FDA: FRESENIUS KABI USA, LLC, ISSUES CORRECTION FOR IVENIX INFUSION SYSTEM LVP SOFTWARE DUE TO ANOMALIES THAT MAY CAUSE DELAY/UNDERDOSAGE OF THERAPY FDA: IDENTIFIED FRESENIUS KABI USA'S RECALL FOR C
F
Reuters - 2 months ago

Formycon And Fresenius Kabi Receive FDA Approval For Fyb202/ Otulfitm

BRIEF-Formycon And Fresenius Kabi Receive FDA Approval For Fyb202/ Otulfitm Sept 30 (Reuters) - FORMYCON AG FYB.DE : AND FRESENIUS KABI RECEIVE FDA APPROVAL FOR FYB202/ OTULFITM(USTEKINUMAB-AAUZ) TULFITMRECEIVED FDA APPROVAL FOR BOTH SUBCUTANEOUS AND INTRAVENOUS FORMULATIONS, TO TREAT SAME CONDITIONS AS STELARA® APPROVAL REPRESENTS THIRD SUCCESSFU
F
Reuters - 2 months ago

FDA Says Fresenius Kabi USA Removes Certain Ivenix Large Volume Pump Primary Administration Sets

BRIEF-FDA Says Fresenius Kabi USA Removes Certain Ivenix Large Volume Pump Primary Administration Sets Sept 16 (Reuters) - FDA: FDA: INFUSION PUMP ADMINISTRATION SET RECALL, FRESENIUS KABI USA REMOVES CERTAIN IVENIX LARGE VOLUME PUMP PRIMARY ADMINISTRATION SETS FDA: FDA IDENTIFIED FRESENIUS KABI USA'S CERTAIN IVENIX LARGE VOLUME PUMP PRIMARY ADMINI
F
Reuters - 2 months ago

Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site

BUZZ-Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank cuts Roche ROG.S to "sell" from "buy", citing limited catalyst due to a risk of Roche creating a lot of sunk cost for little ultimate return ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an
A
B
F
J
R
R
S
P
F
Reuters - 2 months ago

Alstom, Siemens, Tesco

EUROPE RESEARCH ROUNDUP-Alstom, Siemens, Tesco Sept 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alstom, Siemens and Tesco, on Friday. HIGHLIGHTS * Alstom ALSO.PA : HSBC raises target price to EUR 26 from EUR 24 * Hexagon AB HEXAB.ST : HSBC cuts target price to SEK 110 from SEK 120 * Siemens AG SIEGN.DE : HSBC cuts target price to EUR 140 from EUR 150 * Tesco TSCO.L : Citigroup raises target price to 425p from 350p * Travis P
A
A
A
B
B
B
C
C
C
D
D
E
E
F
H
H
I
K
L
L
S
S
S
S
T
T
P
A
A
F
S
U
Reuters - 2 months ago

'Medicine is starting to work', JPM upgrades Fresenius

BUZZ-'Medicine is starting to work', JPM upgrades Fresenius ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an end ** The broker says Fresenius delivered results above expectations in each of the last four quarters and management made progress in improv
F
F
Reuters - 3 months ago

Fresenius Divests IV Manufacturing Site In Chile

BRIEF-Fresenius Divests IV Manufacturing Site In Chile Sept 2 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : DIVESTS IV MANUFACTURING SITE IN CHILE THIS DIVESTMENT INCLUDES IV LABORATORIO SANDERSON PLANT IN SANTIAGO DE CHILE WILL CONTINUE MANUFACTURING OF EXISTING PORTFOLIO OF PRODUCTS IN CHILE FRESENIUS KABI REMAINS COMMITTED TO CHILEAN AS WELL AS S
F

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.